<DOC>
	<DOCNO>NCT00853112</DOCNO>
	<brief_summary>Study assess PF-00489791 efficacy safety Pulmonary Arterial Hypertension ( PAH )</brief_summary>
	<brief_title>A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension</brief_title>
	<detailed_description>Pfizer decide stop trial early upon Stage 1 completion due change PF-00489791 development result safety concern PF-00489791 . Date termination ( LSLV ) occur July 28 , 2010 .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Idiopathic familial pulmonary arterial hypertension ( PAH ) Mean PAP least 25 mm Hg , PCWP &lt; 15 mm Hg rest For female childbearing potential negative pregnancy test screening use contraception study 4 week completion Signed date informed consent Willingness comply study plan procedures pulmonary arterial hypertension ( PAH ) idiopathic familial For female , pregnancy lactation Use specific PAH treatment , potent CYP3A4 inhibitor , protease inhibitor , alpha blocker arginine 30 day prior tio randomization study Change dose class standard background PAH therapy , i.e . oxygen , calcium channel blocker , digoxin , diuretic 30 day prior tio randomization study Large shift altitude ( define &gt; 5000 foot 1524 meter ) 90 day prior baseline visit and/or study visit Subjects intracardiac shunt and/or serious heart , lung health condition HIV positive subject Subjects participate another clinical trial investigational drug device Subjects degenerative retinal disorder , history nonarteritic anterior ischemic optic neuropathy untreated proliferative diabetic retinopathy Allergies previous intolerance PDE5 inhibitor Alcohol drug abuse Blood donation study , 1 month study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>PAH pulmonary hypertension pulmonary arterial hypertension</keyword>
</DOC>